NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

It would appear to be very difficult to achieve statistical significance for a subgroup; more difficult the smaller the subgroup.

However, if the follow-up data for the early unblinded trials recently presented by Linda Liau resembles the current trial data, the mesenchymal subgroup may already be statistically significant. And if not, at least the methylated mesenchymals, assuming the advantage of methylation holds for that subgroup, which seems likely. Early approval of even a small subgroup could provide revenue to complete the trials without any difficulty, if only due to the immediate increase in SP that would result and the investor interest it would garner.

The problem would be that the status of mesenchymal is not outwardly observable. That may be the reason for the strong emphasis on outwardly measurable subgroup divisioning.

Genetic testing to determine subgroups, for example, is a wonderful idea, but I don't know how expensive or accurate it is at this point.

I can't engage anyone in this conversation, but I go on, because I know that Turtle anxiously awaits my every post.